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Objective. Behçet’s disease (BD) is a systemic
inflammatory disease with an incompletely understood
etiology. Despite the identification of multiple common
genetic variants associated with BD, rare genetic var-
iants have been less explored. We undertook this study
to investigate the role of rare variants in BD by
performing whole exome sequencing in BD patients of
European descent.
Methods. Whole exome sequencing was per-
formed in a discovery set comprising 14 German BD
patients of European descent. For replication and vali-
dation, Sanger sequencing and Sequenom genotyping
were performed in the discovery set and in 2 additional
independent sets of 49 German BD patients and 129
Italian BD patients of European descent. Genetic asso-
ciation analysis was then performed in BD patients and
503 controls of European descent. Functional effects of
associated genetic variants were assessed using bioin-
formatic approaches.
Results. Using whole exome sequencing, we iden-
tified 77 rare variants (in 74 genes) with predicted
protein-damaging effects in BD. These variants were
genotyped in 2 additional patient sets and then ana-
lyzed to reveal significant associations with BD at 2
genetic variants detected in all 3 patient sets that
remained significant after Bonferroni correction. We
detected genetic association between BD and LIMK2
(rs149034313), involved in regulating cytoskeletal reor-
ganization, and between BD and NEIL1 (rs5745908),
involved in base excision DNA repair (P 5 3.22 3 1024
and P 5 5.16 3 1024, respectively). The LIMK2 associa-
tion is a missense variant with predicted protein dam-
age that may influence functional interactions with
proteins involved in cytoskeletal regulation by Rho
GTPase, inflammation mediated by chemokine and
cytokine signaling pathways, T cell activation, and
angiogenesis (Bonferroni-corrected P 5 5.63 3 10214,
P 5 7.29 3 1026, P 5 1.15 3 1025, and P 5 6.40 3 1023,
respectively). The genetic association in NEIL1 is a pre-
dicted splice donor variant that may introduce a delete-
rious intron retention and result in a noncoding
transcript variant.
Conclusion. We used whole exome sequencing in
BD for the first time and identified 2 rare putative
protein-damaging genetic variants associated with this
disease. These genetic variants might influence cytoskel-
etal regulation and DNA repair mechanisms in BD and
might provide further insight into increased leukocyte
tissue infiltration and the role of oxidative stress in BD.
Behçet’s disease (BD) is a chronic inflammatory
disease characterized by recurrent oral and genital
ulcers, skin lesions, and uveitis (1). The disease can pre-
sent with systemic manifestations including cardiovascu-
lar, gastrointestinal, musculoskeletal, and neurologic
involvement (1,2). The etiology of BD is incompletely
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understood; however, the disease is thought to be trig-
gered by a dysregulated immune response to environ-
mental stimuli from viruses, certain bacterial species,
and microbial products such as heat-shock proteins (3).
Aberrant epigenetic mechanisms may also contribute to
BD pathogenesis with disease-associated patterns in
DNA methylation that have been identified at several
cytoskeletal genes in monocytes and CD41 T cells from
BD patients (4).
BD also has an important genetic component,
which can be gleaned from an increased disease preva-
lence along the “ancient Silk Road”—a region stretch-
ing from the Mediterranean basin to Japan (5). This
genetic component is further evidenced by familial
aggregation of the disease, with a relative risk in siblings
of affected patients compared to the general population
(ls) ranging from 11.4 to 52.5 in Turkey (6). In addition,
genetic susceptibility for BD has been identified within
the HLA region in multiple ethnic groups (7). Recent
genome-wide association studies have expanded our
understanding of the genetics underlying BD pathogen-
esis by facilitating the discovery of new HLA and non-
HLA susceptibility loci. Indeed, multiple independent
genetic associations have recently been identified in the
HLA region, with the most robust association in BD
localized to an intergenic region between HLAB and
MICA (8–10). Additional genetic risk loci for BD
include a number of non-HLA loci (UBAC2, IL10,
IL23R/IL12RB2, CCR1, STAT4, KLRC4, ERAP1, and
the GIMAP gene cluster) (7).
Whole exome sequencing is quickly becoming a
commonly used high-throughput method for detecting
protein-coding and splice-altering variants, which are
more likely to be protein damaging and thus might have
a more clear effect on disease pathogenesis (11). Fur-
thermore, this technique can be used to detect rare var-
iants which are proposed to contribute to the
heritability of complex disease that remains largely
unexplained by common variants (12). In addition, the
low cost of whole exome sequencing compared to other
sequencing techniques has led to the rapid expansion of
exome databases that make it easy to compare allele fre-
quencies, identify de novo variants, and retrieve previ-
ously reported exome data to use in new studies.
Although whole exome sequencing is already a widely
used approach for detecting genetic variants associated
with monogenic disorders, it is becoming a viable alter-
native technique for elucidating genetic susceptibility in
more complex genetic conditions (11).
Recent discoveries of disease-associated genetic
variants have begun to illuminate the complex genetic
component of BD. However, more research is required
to identify additional susceptibility loci and to determine
the functional relationships between genetic associa-
tions and disease pathogenesis (13). In this study, we
performed the first whole exome sequencing in BD and
identified novel genetic associations by investigating
rare variants with potentially protein-damaging effects
in BD patients of European descent.
PATIENTS AND METHODS
Patient selection and DNA isolation. Whole blood
samples were isolated from BD patients of German or Italian
descent, and genomic DNA was extracted using a QIAamp
DNA Blood Maxi kit in accordance with the instructions of
the manufacturer (Qiagen). All patients fulfilled the 1990
International Study Group criteria for diagnosis of Behçet’s
disease (14). Written informed consent was obtained from all
study participants prior to enrollment, and the study was
approved by the institutional review boards and ethics commit-
tees from each institution involved. A total of 192 BD patients
were studied. Whole exome sequencing was performed in 14
sporadic nonfamilial BD patients from Germany. Two addi-
tional cohorts of 49 German BD patients and 129 Italian BD
patients were included for replication and genetic association
analysis.
Whole exome sequencing. Whole exome sequencing
was performed on genomic DNA that was isolated from whole
blood samples obtained from BD patients. Exome enrichment
was prepared using a TruSeq Exome Enrichment kit
(Illumina), and paired-end 100-bp reads were sequenced on a
HiSeq 2000 instrument (Illumina). Sequence alignment, quali-
ty assurance measures, and data analysis were performed using
a DNA-Seq Analysis Package implemented in SNP & Varia-
tion Suite 7 (Golden Helix) and a Cincinnati Analytical Suite
for Sequencing Informatics (15). Variant filtering was per-
formed using the quality control measures for read depth,
quality score, and a calculated ratio of the alternate allele read
depth to the alternate allele read depth plus the reference
allele read depth, as previously described (16). Synonymous
variants were excluded from further analysis.
Sanger sequencing. Sanger sequencing was performed
in our discovery cohort for select variants in ALOX15B, IL21R,
MYO15A, PKP1, and PKP3. Sanger sequencing confirmed
whole exome sequencing results 100% of the time. Primers
were designed using Primer3 software (Premier Biosoft), and
primer quality was assessed using NetPrimer software (Premier
Biosoft) (17). The following primers were used: for ALOX15B,
50-ATTTGAGTGACCCCGTTCC-30 (forward) and 50-GAGG-
AGTGTGTTTCGGGAGA-30 (reverse); for IL21R, 50-GCCT-
TGAAACATTGGTGCTC-30 (forward) and 50-AGTCCTG-
TGAGCCCTGAGTG-30 (reverse); for MYO15A, 50-GGAC-
CTGGGCGAGTATTATG-30 (forward) and 50-GGGAGGT-
CATAGGGTGGGTA-30 (reverse); for PKP1, 50-CCCTCTT-
CCACCCTCTTCTC-30 (forward) and 50-CCACTCCTGTAG-
CCACCACT-30 (reverse); and, for PKP3, 50-GCAAAGGCAG-
AAGCAGAGG-30 (forward) and 50-ACCACCAGGTTGTT-
GAGCAC-30 (reverse). Polymerase chain reaction (PCR) was
performed on a T100 thermocycler (Bio-Rad) using ZymoTaq
one-step master mix (Zymo) and the following settings: 958C
for 10 minutes; 40 cycles of 958C for 30 seconds, 58.38C for 40
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seconds, and 728C for 1 minute; and 728C for 7 minutes. PCR
amplification was then confirmed by agarose gel electrophoresis
(2% agarose gel). The PCR-amplified DNA was purified and then
sequenced using a 3730 XL sequencer (Applied Biosystems).
Sequenom genotyping. Sequenom genotyping was
performed on all BD patient samples at the University of Michi-
gan DNA Sequencing Core. Genotyping assays were designed
for 73 of the 77 target variants using an Assay Design Suite
(Agena Bioscience) and MassArray Assay Design 4.0 (Seque-
nom). Assays could not be created for rs80096349, rs143211074,
rs145837446, and rs138771398 within AGER, BTNL2, SPPL2C,
and TNXB, respectively. Genotyping assays were performed
using the MassArray System according to the standard proto-
cols of the manufacturer (Agena Bioscience). Single-nucleotide
polymorphism (SNP) calls were automatically generated using
TyperAnalyzer software (Sequenom) and then validated manu-
ally to exclude SNPs with ambiguous spectra.
Statistical analysis of genotyping data. Quality con-
trol measures were applied to Sequenom genotyping data to
include individuals with a genotyping success rate of .90% for
all variants, and then to include variants with a genotyping suc-
cess rate of .90% for all individuals. Genotyping data were
obtained from 503 healthy controls of European descent includ-
ed in the 1000 Genomes Project (18). Association analyses were
then performed using a basic allelic chi-square test with 1df via
a Plink version 1.07 whole-genome data analysis toolset (19).
Bioinformatic analyses. Protein-damage predictions
were made using SIFT, Polyphen2, MutationTaster, Mutation
Assessor, and FATHMM algorithms included in SNP & Varia-
tion Suite 7 (20–24). For noncoding variants, an additional pre-
diction was made using the FATHMM-MKL algorithm (24,25).
Conservation was assessed using PhastCons and PhyloP algo-
rithms for which we defined highly conserved loci as having a
PhastCons score of .0.95 and a PhyloP score of .3.00 (26,27).
Structural data were acquired for LIM domain kinase 2
(LIMK2) (UniProtKB accession no. P53671; Research Collabo-
ratory for Structural Bioinformatics Protein Data Bank [RCSB
PDB] ID no. 4TPT) and Nei-like DNA glycosylase 1 (NEIL1)
(UniProtKB accession no. Q96FI4) from the RCSB PDB
(28,29), and crystal structures were visualized using Visual
Molecular Dynamics software version 1.9.2 (30). The predicted
effects of the S605C residue change on LIMK2 secondary struc-
tures and disulfide bond formation were determined using
PsiPred and PredictProtein software, respectively (31–33). Func-
tional protein interactions were determined using STRING 10
software with a confidence threshold of 0.800, and results were
filtered to include activation, inhibition, binding, catalysis, post-
translational modifications, and reaction-based interactions
(34,35). Pathway enrichment analyses were performed using Pan-
ther Pathway annotations and DAVID (36,37).
RESULTS
Enrichment of rare genetic variants with puta-
tive protein-damaging potential. In a discovery cohort
comprising 14 BD patients of European descent, we
explored exon and splice site variants using whole
exome sequencing. Variants were initially filtered using
the quality control measures as previously described
(16). Variants that can alter the amino acid protein
sequence were then filtered to include those observed in
at least 2 of the 14 sequenced patients and previously
reported with a minor allele frequency (MAF) of ,0.01
in a population of 6,503 individuals (Exome Variant
Server; National Heart, Lung, and Blood Institute
[NHLBI] Grand Opportunity [GO] Exome Sequencing
Project) (http://evs.gs.washington.edu/EVS/). Variants
were then analyzed for the potential to induce protein-
damaging effects using SIFT, Polyphen2, Muta-
tionTaster, Mutation Assessor, and FATHMM func-
tional prediction algorithms (20–24). Our analyses
identified 77 rare variants in 74 genes with protein-
damaging potential as predicted by at least 1 prediction
algorithm. These variants included 73 nonsynonymous var-
iants, 1 stop-gain variant, and 3 splice site variants (see
Supplementary Table 1, available on the Arthritis & Rheu-
matology web site at http://onlinelibrary.wiley.com/doi/10.
1002/art.39545/abstract). We identified multiple putative
protein-damaging variants in the SNX8 and TTN genes,
which contained 2 and 3 variants, respectively.
Genetic association analysis. The putative protein-
damaging variants were genotyped in the original 14
sequenced patients and 2 additional cohorts of 49 Ger-
man BD patients and 129 Italian BD patients by Seque-
nom genotyping. In addition, genotyping data were
obtained for 503 healthy controls of European descent
included in the 1000 Genomes Project (18). We then
applied quality control filters and performed a genetic
association analysis for a total of 61 successfully geno-
typed variants in 178 BD patients and 503 healthy con-
trols using a basic allelic chi-square test with 1df. Our
results confirmed 2 novel genetic associations that
remained significant after Bonferroni correction for mul-
tiple testing (P , 8 3 1024). The Bonferroni-corrected P
value threshold was derived using an alpha level of 0.05
and 61 independent genetic variants tested (0.05/61 5 8 3
1024). These 2 BD-associated rare variants were
rs149034313 (odds ratio [OR] 17.23, P 5 3.22 3 1024), a
missense variant within LIMK2, and rs5745908 (OR 4.35,
P 5 5.16 3 1024), a splice site variant within NEIL1
(Table 1) (see Supplementary Table 2, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.39545/abstract).
Analyses of the putative protein-damaging effects
of LIMK2 and NEIL1 associations. We explored the
putative protein-damaging effects of rs149034313 and
rs5745908 within LIMK2 and NEIL1, respectively. The
association in LIMK2 (rs149034313) is found at a highly
conserved locus with a high probability of inducing a
protein-damaging effect (MutationTaster2 probability
of 0.99999). Specifically, this variant introduces an
S605C residue change within the LIMK2 protein tyro-
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sine kinase domain that is responsible for serine- and
threonine-specific protein phosphorylation (38). We
examined how S605C interacts with residues involved in
LIMK2 catalysis using the crystal structure of the homo-
dimeric protein kinase domains. The structure shows
that S605C is localized to a C-terminal a-helix that is
distal to the ATP binding site and active site at residues
360 and 451, respectively (38,39) (Figure 1). The S605C
a-helix is also distant from key structural residues relat-
ed to LIMK2 activity (Leu337, Phe342, Ala345, Val358,
Lys360, Leu389, Ile408, Leu458, Asp469, Gly471, and
Leu472) (40) (Figure 1). We then assessed whether the
residue change affected LIMK2 secondary structures
and disulfide bond formation. However, there was no
predicted change to the S605C a-helix, and no new
disulfide bonds were predicted to form at S605C.
The association in NEIL1 (rs5745908) is located 2-
bp downstream of an exon splice site in an intron between
the first 2 exons of the NEIL1 exon structure (UniProtKB
accession no. Q96FI4) (41) (Figure 2A). This variant was
predicted to be deleterious to NEIL1 with high probability
(FATHMM-MKL probability of 0.96693; MutationTaster2
probability of 1.00000) (22,25). In addition, this NEIL1
association is a predicted splice donor variant, a type of
variant that can induce intron retentions that lead to non-
coding transcripts via mechanisms of nuclear sequestration
and nonsense-mediated decay, as introns often contain
premature stop codons. Similarly, intron retention by this
NEIL1 variant is predicted to result in a premature intron
stop codon, such as in NEIL1-012 (Ensembl transcript ID:
ENST00000564951), a noncoding NEIL1 transcript (Fig-
ure 2B).
Functional pathway analyses of LIMK2 and
NEIL1. We investigated downstream effects of the puta-
tive protein damage from the disease-associated variants by
exploring the affected functional pathways. For LIMK2, we
Table 1. Genetic association analysis results for rare variants that
were significantly associated with BD following Bonferroni correc-
tion (P , 8 3 1024)*
Gene name
LIMK2 NEIL1
SNP (minor allele) rs149034313 (G) rs5745908 (C)
Genomic position (HG19) Chr. 22: 31674324 Chr. 15: 75641682
Codon change TCC ! TGC NA
MAF in cases 0.017 0.034
MAF in controls 0.001 0.008
P 3.22 3 1024 5.16 3 1024
OR (95% CI) 17.23 (2.07–143.60) 4.35 (1.76–10.74)
* The analysis included 178 patients with Behçet’s disease (BD) and
503 healthy controls of European descent. SNP 5 single-nucleotide
polymorphism; HG19 5 human genome version 19; Chr. 5 chromo-
some; NA 5 not applicable; MAF 5 minor allele frequency;
OR 5 odds ratio; 95% CI 5 95% confidence interval.
Figure 1. A, Protein map depicting functional and structural features of LIM domain kinase 2 (LIMK2) relative to rs149034313. Functional sites
are shown with the ATP-binding site and the active site as cyan and yellow markers, respectively. In addition, secondary structures are shown
with a-helices and b-sheets as red and yellow blocks, respectively. B and C, Crystal structures depicting the homodimeric protein kinase domains
of LIMK2 to show the S605C residue change (green) relative to the active site (yellow) and ATP-binding site (cyan) (B) and to key structural
residues (purple) (C). LIM 5 LIM protein structural domain; PDZ 5 PDZ protein structural domain.
RARE PROTEIN-CODING VARIANTS IN BD 1275
identified functional interactions with 13 proteins with high
confidence ($0.800) (Figure 3). We then analyzed the
LIMK2-interacting proteins for biologic pathways to identi-
fy a highly significant enrichment for cytoskeletal regulation
by Rho GTPase (Bonferroni-corrected P 5 5.63 3 10214,
false discovery rate [FDR] of 2.86 3 10212) (Table 2).
Significant enrichment was also found in pathways
involved in inflammation mediated by chemokine and
cytokine signaling (Bonferroni-corrected P 5 7.29 3
1026, FDR of 3.71 3 1024), T cell activation (Bonfer-
roni-corrected P 5 1.15 3 1025, FDR of 5.88 3 1024),
and angiogenesis (Bonferroni-corrected P 5 6.40 3 1023,
Figure 2. A, Protein map depicting functional and structural features of Nei-like DNA glycosylase 1 (NEIL1) relative to rs5745908. Functional
sites are shown with DNA binding sites and active sites as purple and yellow markers, respectively. In addition, secondary structures are shown
with a-helices and b-sheets as red and yellow blocks, respectively. B, Transcript variants for NEIL1 with respect to rs5745908, highlighting the
retained intron of noncoding transcript NEIL1-012.
Figure 3. Diagram depicting LIM domain kinase 2 (LIMK2) functional interactions with proteins based on activation, inhibition, binding, and
posttranslational modifications. Interactions are represented by lines with a thickness that corresponds to the confidence level. The diagram was
generated using STRING 10 software. CFL1 5 cofilin 1; ROCK1 5 Rho-associated coiled-coil–containing protein kinase 1; PAK4 5 p21 protein
(Cdc42/Rac)–activated kinase 4; PARD3 5 par-3 family cell polarity regulator; NISCH 5 nischarin.
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FDR of 0.327). In our analysis of NEIL1 functional inter-
actions, we identified 4 proteins with high confidence
($0.800) (Figure 4). However, pathway analysis of these
proteins revealed no significantly enriched pathways.
DISCUSSION
Accumulating evidence suggests that rare variants
make an important contribution to complex disease.
Although these variants are infrequent, separate rare var-
iants present in different individuals may lead to the
same disease by affecting related pathways (42). In addi-
tion, rare variation is proposed to contribute to the heri-
tability of complex diseases, which is mostly unexplained
by common variants (12). In this first whole exome
sequencing study in BD, we identified and verified the
presence of rare variants with predicted protein-
damaging effects in patients of European descent in a
discovery cohort and in 2 additional independent cohorts.
Our sample size had .90% power to detect a genetic
association of a variant with an MAF of 0.01 and an OR
of 4.0 (a 5 0.05, disease prevalence of 5.2/100,000).
We identified and replicated significant genetic
associations with protein-damaging potential in LIMK2
and NEIL1. The most significant association was local-
ized to a highly conserved locus within LIMK2
(rs149034313), an important regulator of actin cytoskel-
etal reorganization (43). Characterization of this associ-
ation showed that the variant induces an S605C residue
change in the LIMK2 protein kinase domain. However,
the location of S605C suggests a low likelihood that it
will affect the catalytic mechanism or function-related
Figure 4. Diagram depicting Nei-like DNA glycosylase 1 (NEIL1) functional interactions with proteins based on activation, inhibition, binding,
and posttranslational modifications. Interactions are represented by lines with a thickness that corresponds to the confidence level. The diagram
was generated using STRING 10 software. WRN 5 Werner syndrome RecQ-like helicase; HUS1 5 HUS1 checkpoint clamp component;
RAD9A 5 RAD9 checkpoint clamp component A; RAD1 5 RAD1 checkpoint DNA exonuclease.







Cytoskeletal regulation by Rho
GTPase
26.21 5.63 3 10214 2.86 3 10212 PAK6, CDC42, PAK7, PAK2, ROCK1,
ROCK2, PAK3, CFL2, PAK4, CFL1, PAK1
Ras pathway 20.20 2.04 3 1026 1.04 3 1024 PAK6, CDC42, PAK7, PAK2, PAK3, PAK4,
PAK1
Axon guidance mediated by
semaphorins
31.80 3.70 3 1026 1.89 3 1024 PAK6, PAK7, PAK2, PAK3, PAK4, PAK1
Inflammation mediated by
chemokine and cytokine signaling
pathway
7.69 7.29 3 1026 3.71 3 1024 PAK6, CDC42, PAK7, PAK2, ROCK1,
ROCK2, PAK3, PAK4, PAK1
T cell activation 15.15 1.15 3 1025 5.88 3 1024 PAK6, CDC42, PAK7, PAK2, PAK3,
PAK4, PAK1
Angiogenesis 7.02 6.40 3 1023 3.27 3 1021 PAK6, PAK7, PAK2, PAK3, PAK4, PAK1
* Enrichment was performed using DAVID with Panther Pathway annotations (36,37). FDR 5 false discovery rate; PAK6 5 p21 protein (Cdc42/
Rac)–activated kinase 6; ROCK1 5 Rho-associated coiled-coil–containing protein kinase 1; CFL2 5 cofilin 2.
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structural features due to its distance from the nucleo-
tide binding region, ATP binding site, active site, and
key structural residues (38–40). In addition, protein-
modeling algorithms showed that S605C would not
interrupt secondary protein structures, and the cysteine
residue change is unlikely to form new disulfide bonds
within the known crystallized portion of the protein.
However, the location of S605C on the surface of
LIMK2 may render it more susceptible to damage by
posttranslational modifications. Cysteine thiol groups
are known targets of both reactive oxygen species
(ROS) and reactive nitrogen species, which can induce
a number of reversible and irreversible posttranslational
modifications to proteins at critical cysteines (44). These
modifications could potentially affect a protein’s charge
and/or structure, thereby changing its function, location,
or association with other proteins.
Of course, further studies will be required to elu-
cidate the specific effect of this residue change on
LIMK2 and to determine whether this amino acid
change will affect LIMK2 interactions with other pro-
teins. Due to the high number of LIMK2 activators and
modifiers, there is a strong possibility that functional
interactions are affected by the residue change.
We next investigated the impact of putative dam-
age of LIMK2 protein on cellular pathways. Our analy-
sis revealed LIMK2 interactions with 13 proteins that
were significantly enriched for several BD-associated
pathways including angiogenesis, inflammation, T cell
activation, and cytoskeletal regulation. Indeed, BD
pathogenesis has been linked to abnormal levels of sev-
eral angiogenic factors such as angiopoietin 1 (45,46),
monocyte chemoattractant protein 1 (47), serum vascu-
lar endothelial growth factor (48), and soluble VE-
cadherin (49). BD is also associated with tissue inflam-
mation, which is accompanied by leukocyte infiltration,
predominantly from T cells and monocytes (50–52). In
addition, cytoskeletal remodeling is central to leukocyte
adhesion and infiltration in BD, and the genes involved
in this remodeling exhibit dysfunctional DNA methyla-
tion that reverses upon disease remission (4). Cytoskele-
tal remodeling is also directly regulated by LIMK2
through the phosphorylation/inactivation of cofilin, a
protein responsible for actin filament depolymerization.
This induces the formation of stress fibers and focal com-
plexes in response to LIMK2 activation by Rho and Cdc42
pathways, respectively (43). Importantly, this process is
directly relevant to the leukocyte motility and tissue infil-
tration that are increased in BD patients.
In addition, LIMK2 has been shown to play a
role in extracellular matrix adhesion in the epidermal
basal layer, and the expression of a related LIM kinase
(LIMK1) has been shown to be down-regulated and
involved in the pathogenesis of psoriasis (53). Up-
regulation of cofilin and LIMK2 has been described in a
model of pulmonary artery inflammation (54), a charac-
teristic and serious clinical feature in some patients with
BD (55). Recent studies have also identified a role for
LIMK2 in the stress response pathway as a transcrip-
tional target of p53. In this role, genotoxic stress up-
regulated LIMK2 to cause a “pro-survival” cell cycle
arrest at the G1 phase (56). Conversely, LIMK2 inhibi-
tion rendered cells more susceptible to apoptosis when
exposed to genotoxic stress. Therefore, putative damage
of LIMK2 protein may increase apoptosis susceptibility
in response to the oxidative stress that is increased in
active BD (57). Taken together, LIMK2 has a central
role in the complex cellular pathways that are implicated
in BD pathogenesis, and the association detected at
rs149034313 might present a novel disease target for
future studies.
We detected a second rare variant BD associa-
tion within NEIL1, which encodes a DNA glycosylase
involved in initiating the base excision repair (BER)
pathway (58). This association is a predicted splice
donor variant which has deleterious effects on NEIL1
by inducing intron retention and introducing a prema-
ture intron stop codon exactly like that in NEIL1-012
(ENST00000564951), a noncoding NEIL1 transcript.
Given the role of NEIL1 in BER initiation, this deleteri-
ous effect could have extensive consequences for DNA
damage repair following oxidative stress, especially
because NEIL1 is important in repairing mutagenic oxi-
datively modified bases (58). Importantly, BD inflam-
mation exposes cells to abnormal levels of ROS, and
DNA damage repair machinery is essential for manag-
ing the effects of this oxidative stress.
In this study, we performed the first whole exome
sequencing in BD and then identified and confirmed
significant novel genetic associations in patients of
European descent. Further analysis of these associations
revealed potential protein-damaging effects in LIMK2
and NEIL1, which play considerable roles in cell motili-
ty and DNA damage repair. As these functions are para-
mount to the leukocyte infiltration and oxidative stress
that are increased in BD, the rare variant associations
identified might present novel disease targets and key
pathways to explore in future studies.
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